Breaking News, Promotions & Moves

AffyImmune Names Chief Medical Officer

Dr. Deyaa Adib brings over 28 years of experience in pharmaceutical research and development in oncology to the biotechnology company.

Author Image

By: Charlie Sternberg

Associate Editor

AffyImmune Therapeutics, a clinical-stage biotechnology company, has appointed Deyaa Adib, M.D., as Chief Medical Officer (CMO).   Dr. Adib brings over 28 years of experience in pharmaceutical research and development in oncology, including the advancement of clinical-stage engineered T cell therapies. He will oversee all clinical activities for AffyImmune, including the strategic direction and execution of clinical development programs, leading the efforts and teams in clinical operations, cl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters